Navigation Links
New therapy reduces mortality in patients with severe COPD
Date:12/28/2007

Patients with severe COPD may benefit more from therapy that combines salmeterol and fluticasone [SFC] than treatment with tiotropium, according to results from a long-term, multi-center study, Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) that directly compared the two therapies.

Although we found no difference in the overall rate of exacerbations between treatment groups, SFC treatment was associated with better health status, fewer patient withdrawals, and a lower mortality rate than occurred during tiotropium therapy, said lead author if the study, Jadwiga Wedzicha, M.D., of the Royal Free & University College Medical School in London

This was the first large-scale trial to directly compare the two different treatment approaches. The results appeared in the first issue for January of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

The researchers recruited 1,323 patients with severe COPD and randomized them to receive one of two treatmentseither SFC or tiotropiumfor two years. They analyzed number and type of exacerbations, health status as measured by the St. Georges Respiratory Questionnaire (SGRQ), lung function (post-dose forced expiratory volume in one second) and study withdrawal rate. The study was double-blinded and double-dummy controlled, and all patients underwent identical intensification of treatment before beginning the trial to standardize their clinical conditions.

While exacerbation rates between the two treatment groups were statistically indistinguishable, there were differences in the treatment that the exacerbations required. Oral corticosteroids were used more often to treat the tiotropium group, whereas patients on SFC required antibiotics more frequently.

This finding provides indirect evidence that these treatments affect apparently similar patients in different ways that affect clinical judgmen
'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Catalent Pharma Solutions, the leading ... solutions for drugs, biologics and consumer health products, ... Supply Services, and Chris Greco, Manager, Comparator and ... for Active Control Clinical Trials” at the forthcoming ... on the 9th – 10th September, 2014 in ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... an investigational vaccine to prevent Ebola virus disease will ... and Infectious Diseases (NIAID), part of the National Institutes ... human testing of a vaccine co-developed by NIAID and ... and ability to generate an immune system response in ... Clinical Center in Bethesda, Maryland. , The study is ...
(Date:8/28/2014)... treated with nasal septum cells. Researchers at the University ... taken from the nasal septum are able to adapt ... thus repair articular cartilage defects. The nasal cartilage cells, ... is associated with the expression of so-called HOX genes. ... published the research results together with the report of ...
(Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
Breaking Medicine News(10 mins):Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Drug shows promise for subset of stage III colon cancer patients 2
... Offers Hope to Millions of Couples Seeking a Better Sex,Life, ... relieved by the,preliminary results of a new study that demonstrates ... lives. The exercises take,just 5 minutes a day but the ... who followed the simple PelvicToner exercise,programme reported an improved sex ...
... to farms, particularly to barns and farm milk, while ... to a group of German researchers, who will present ... Conference in Toronto on Wednesday, May 21., In a ... 59 non-farming mothers, the researchers believe they have proved ...
... their Prescription History, WALNUT CREEK, Calif., May ... ) announced today a new collaboration with,Google Health ... between,patients and providers. Working with Google, Longs will ... customers with the ability to import their,prescription information ...
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... over T-cell counts for monitoring HIV treatment , ... can help identify those whose treatment will succeed or ... from pharmacy records, works at least as well as ... the immune system, according to research published in PLoS ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
Cached Medicine News:Health News:Is Female Sexual Dysfunction a Myth? 2Health News:Farm moms may help children beat allergies 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 2Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 3Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 4Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 5Health News:Mapping of prostate cancer genes opens the door to new treatments 2
(Date:8/28/2014)... Colo. , Aug. 28, 2014   Venaxis, ... company focused on obtaining FDA clearance for and commercializing ... blood test for aiding in identifying children, adolescent, and ... at low risk for appendicitis, today announced it will ... Renshaw 16 th Annual Global Investment Conference being ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... MAHWAH, N.J. , Aug. 28, 2014  Stryker Orthopaedics, ... Champions Tour, is bringing its message of joint health to ... Playoffs this week at the Deutsche Bank Championship. The company,s ... in the "Fairway Fan Zone on 9" at the TPC ... Thursday, August 28 th .    At the ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5
... 2007 - OSI,Pharmaceuticals, Inc. (Nasdaq: OSIP) announced ... of Clinical Oncology show that,adding Tarceva(R) (erlotinib) ... as first-line,therapy to patients with advanced pancreatic ... National Cancer Institute of Canada (NCIC),formed the ...
... STRASBOURG, France and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ ... pharmaceutical and medical device company, announced that,the ... examining the,Vascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will ... in Europe. The,two-year study examined the safety ...
Cached Medicine Technology:OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
... The Models 512 and 513 handheld ... This advanced technology is able to ... resolutions and speeds of 100 times ... in improved pulse oximeter performance during ...
... Whether it's for an emergency situation, bedside ... Handheld Capnograph / Pulse Oximeter delivers accurate ... This portable, handheld monitor now contains Nellcors ... compatible with OxiMax sensors. The NPB-75 monitor ...
The new Nellcor N-45 Handheld Pulse Oximeter is compatible with our complete line of OxiMax Pulse Oximetry Sensors, so clinicians have the convenience of Nellcors most advanced sensor technology in a...
Medicine Products: